Not-For-Profit Partnership with Eli Lilly and Company for TB Early Phase Drug Discovery
The Partnership
In 2007, as part of their philanthropic effort in multidrug-resistance tuberculosis, Eli Lilly and Company announced the Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery. This unique endeavor is designed to accelerate discovery and development of new drugs to fight TB. The ultimate aim is to make treatment of TB more effective, accessible, and affordable.
The partnership will be based in Seattle, Washington, at the Infectious Disease Research Institute (IDRI). Partners include:
- Eli Lilly & Company
- National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
- Afya World Medicines
- Infectious Disease Research Institute
- Jubilant Biosys
- Merck and Company
- Seattle Biomedical Research Institute (SBRI)
- University of Washington Department of Global Health
Goals
- Integrate key scientific disciplines needed for sustained discovery of new medicines to treat TB
- Bring together leading scientists to share capabilities and expertise in TB research and drug discovery
- Make medicinal chemistry and associated technologies readily available to TB researchers
- Enable new drug candidates to enter the research and development pipeline
- Enhance the early stage TB pipeline for developers such as the Global Alliance for TB Drug Development—a not-for-profit, product development partnership
What You Can Do
If you have candidate compounds or validated targets that may be suitable for TB drug development, contact Dr. Gail Cassell at Lilly: g.cassell@lilly.com or Dr. Barbara Laughon at NIAID: blaughon@niaid.nih.gov or +1 301-402-0138.
News Releases
Statement of Christine F. Sizemore, Ph.D., Barbara E. Laughon, Ph.D., and Anthony S. Fauci, M.D., on World TB Day—Mar. 24, 2008
Lilly Unveils Ambitious Partnership for Tuberculosis Drug Discovery—June 13, 2007 (Eli Lilly and Company)
back to top